- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Buprenorphin
Camurus: Transforming treatments by long-acting medications
Fredrik Tiberg, President & CEO
Pdf-Präsentation zu CAM 2038, Weekly and monthly buprenorphine depots - Changing the treatment paradigm in opioid dependence (ohne Datum)
Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
Khazaeli A, Jerry JM, Vazirian M.
J Addict Med. 2018 Nov/Dec;12(6):493-495. doi: 10.1097/ADM.0000000000000435.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30383616
The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.
Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, Nasrallah H, Amore M.
Int J Mol Sci. 2018 Aug 15;19(8). pii: E2410. doi: 10.3390/ijms19082410.
http://www.mdpi.com/1422-0067/19/8/2410
Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Azar P, Nikoo M, Miles I.
Am J Addict. 2018 Nov 2. doi: 10.1111/ajad.12809.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30387894
Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
Roux P, Rojas Castro D, Ndiaye K, Briand Madrid L, Laporte V, Mora M, Maradan G, Morel S, Spire B, Carrieri P.
Subst Abuse Treat Prev Policy. 2017 Nov 2;12(1):46. doi: 10.1186/s13011-017-0131-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667450/
CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU
A final decision by the European Commission is expected November 2018. (Camurus, 21.09.2018)
USA. FDA Nixes Approval of Buprenorphine Spray for Pain
Today the US Food and Drug Administration (FDA) turned down approval of Buvaya, a buprenorphine sublingual spray (INSYS Therapeutics) for moderate to severe pain resulting from reported safety concerns. (Medscape, 27.07.2018)
https://www.medscape.com/viewarticle/899924
Understanding the use of diverted buprenorphine.
Cicero TJ, Ellis MS, Chilcoat HD.
Drug Alcohol Depend. 2018 Oct 12;193:117-123. doi: 10.1016/j.drugalcdep.2018.09.007.
https://www.ncbi.nlm.nih.gov/pubmed/30359928
Buprenorphin-Naloxone: Mundipharma bringt Zubsolv®
Berlin- Die Substitutionstherapie opioidabhängiger Patienten erfolgt durch medizinische, soziale und psychotherapeutische Maßnahmen. Mundipharma bringt mit Zubsolv neue Sublingualtabletten mit Buprenorphin und Naloxon auf den Markt. (apotheke adhoc, 17.05.2018)
Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine.
Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R.
Patient Prefer Adherence. 2018 Oct 11;12:2123-2129. doi: 10.2147/PPA.S180641.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
Jönsson M, Mundin G, Sumner M.
Eur J Pharm Sci. 2018 Jun 22;122:125-133. doi: 10.1016/j.ejps.2018.06.024.
Abstract
https://www.sciencedirect.com/science/article/pii/S092809871830280X
Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder.
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA.
Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165853/
Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities
Sarah E. Wakeman, M.D., and Michael L. Barnett, M.D.
N Engl J Med 2018; 379:1-4, DOI: 10.1056/NEJMp1802741
https://www.nejm.org/doi/full/10.1056/NEJMp1802741
High buprenorphine-related mortality is persistent in Finland.
Kriikku P, Häkkinen M, Ojanperä I.
Forensic Sci Int. 2018 Aug 17;291:76-82. doi: 10.1016/j.forsciint.2018.08.010.
Abstract
https://www.sciencedirect.com/science/article/pii/S0379073818305073?via%3Dihub
Buprenorphine - Drugs and Lactation Database
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Last Revision: June 4, 2018.
https://www.ncbi.nlm.nih.gov/books/NBK501202/
Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet].
Harricharan S, Farah K.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul 31.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0099978/
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S.
JAMA Intern Med. 2018 May 14. doi: 10.1001/jamainternmed.2018.1052.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29799968
USA. FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Agency is taking additional steps to advance the development of new FDA-approved treatments for opioid dependence and encourage their more widespread use.
The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths. (FDA - U.S. Food and Drug Administration, 07.09.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm619864.htm
Die Umstellung von y-Agonisten auf Buprenorphin
Dr.med.F. Matschinski, Schwerpunktpraxis für Suchtmedizin Ravensburg
Präsentation (Folien) von der DSÄ-Fortbildungsveranstaltung vom 14.04. in Köln-Sürth
USA. OxyContin maker gets patent for drug to treat opioid addiction
Purdue Pharma, the maker of OxyContin, has received a patent designed to treat opioid addiction.
The patent, first reported by The Financial Times, is for a new and faster-acting form of buprenorphine. (CBS-News, Money Watch, USA, 07.08.2018)
https://www.cbsnews.com/news/oxycontin-maker-receives-patent-for-drug-to-treat-opioid-addiction/
Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.
Jaureguiberry-Bravo M, Lopez L, Berman JW.
J Leukoc Biol. 2018 May 23. doi: 10.1002/JLB.3HI0118-015R.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29791013
USA. OxyContin Billionaire Patents New Drug for Opioid Treatment
In recent years, America’s pharmaceutical industry has taken it on the chin. Populist demagogues have savaged drug companies for “jacking up” the price of life-saving substances like insulin (a.k.a. honoring their fiduciary duty to maximize shareholder value). These boisterous neo-Bolsheviks will point to the fact that pharmaceuticals are several times more expensive in the U.S. than in other countries, and conclude that our government’s exceptionally strong patent laws — and aberrant refusal to push down drug prices through direct negotiation — are meant to enrich Big Pharma at the working American’s expense. (Daily Intelligencer, USA, 07.09.2018)
USA. San Francisco will bring anti-addiction medication to users on the streets
(...) The city announced Thursday that its medical providers will offer buprenorphine and naltrexone prescriptions at needle exchanges, in parks and in other places where people with opioid disorders congregate. Users will be able to pick up the medications, which block the craving for opioids and the painful symptoms of withdrawal, at a centrally located city-run pharmacy. (Washington Post, 17.05.2018)
MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, Goldblatt J, Xie HY, Marsch LA.
Addict Sci Clin Pract. 2018 Sep 24;13(1):21. doi: 10.1186/s13722-018-0122-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154900/
The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.
Contemp Clin Trials. 2018 Apr 5;69:21-27. doi: 10.1016/j.cct.2018.04.001.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29627621
The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
Ahmadi J, Jahromi MS, Ehsaei Z.
Trials. 2018 Aug 29;19(1):462. doi: 10.1186/s13063-018-2843-9.
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2843-9
Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
Kowalczyk WJ, Moran LM, Bertz JW, Phillips KA, Ghitza UE, Vahabzadeh M, Lin JL, Epstein DH, Preston KL.
Am J Drug Alcohol Abuse. 2018 Apr 10:1-10. doi: 10.1080/00952990.2018.1454933.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29634425
SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.
Substance Abuse and Mental Health Services Administration
[US] Substance Abuse and Mental Health Services Administration, 2018
https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf
Seite 1 von 6
